Obviously this segment of research and development is dynamic with continuous change, with new developments forced by positive research outcomes - and Clarity is at the forefront of the Medical Research. The latest update to that above-referred article is:
"Molecules. 2022 Mar; 27(5): 1501. Published online 2022 Feb 23. doi: 10.3390/molecules27051501PMCID: PMC8912090PMID: 3526860067Cu Production Capabilities: A Mini Review"
In particular I refer to Clarity's agreement with Northstar, as quoted from the latest Annual Report:
"Our commercial-scale copper-67 supplier, NorthStar Medical Radioisotopes (NorthStar), is now routinely producing the radioisotope using their large-scale, highly efficient, environmentally preferable electron accelerator technology. NorthStar has now supplied copper-67 for clinical trial participants, with the first participant of the highest dose escalation cohort in the CL04 theranostic trial in neuroblastoma, an aggressive childhood cancer, receiving Northstar’s copper-67.
"NorthStar complements our ongoing supply from the Idaho Accelerator Center, which has been supplying us copper-67 for all of our pre-clinical and clinical development over the last 8 years."
Ann: Completion of Placement and Institutional Entitlement Offer, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.36 |
Change
0.055(0.87%) |
Mkt cap ! $1.985B | |||
| Open | High | Low | Value | Volume |
| $6.32 | $6.48 | $6.29 | $2.610M | 410.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 5138 | $6.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.36 | 793 | 1 |
View Market Depth
| Last trade - 13.20pm 26/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |